EXEL Exelixis, Inc. - Common Stock
$54,24
Precio · Ago 19, 2026
Fundamentales a fecha de Ago 5, 2026
Rango 52S
$34–$58
86% of range
Calificación del Analista
HOLD
26 analysts
Precio Objetivo
$53
P/E (TTM)
18.9
ROE
37.3%
Margen de Beneficio Neto
33.7%
Acerca de Exelixis, Inc. - Common Stock Descripción general de la empresa de Wikipedia
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Leer más
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
History
Exelixis was founded in 1994; the scientific founders were Spyridon Artavanis–Tsakonas, at Yale at that time, and Corey Goodman and Gerry Rubin who were then at the University of California, Berkeley. George Scangos joined the company as CEO in 1996. The business plan was to use model organisms (fruit flies, nematodes, and zebrafish) and functional genomics to identify pathways and biological targets that could be exploited in the fields of agriculture and medicine. It eventually set up a subsidiary, Exelixis Plant Sciences, for the agricultural work.
By 2000, Exelixis had left the radical exploratory phase behind and became focused on drug discovery and had a chemical library of 4 million compounds. The company went public that year, after withdrawing its offering the week before; it raised $118 million in a down market.
In 2002, the company signed a broad alliance with GSK to discover new drugs in the fields of cancer, inflammatory diseases, and vascular conditions; GSK paid it $30 million in cash, bought $14 million in stock at twice the market rate, and committed to providing Exelixis with $90 million in research funding; it also offered loan financing of up to $85 million.
By 2002, the company had limited its internal efforts to cancer, and had settled its strategy on discovering and developing drugs that could inhibit targeted small sets of tyrosine kinases that are needed for cancer formation, growth, and metastasis. The sets of TKs had been identified by means of its prior functional genomics work. This approach was controversial at the time; most companies try to selectively target just one protein in their discovery efforts.
In 2006, Exelixis partnered with Daiichi Sankyo on compounds that targeted mineralocorticoid receptors; esaxerenone was part of this collaboration. In 2007, the company partnered its MEK inhibitor program with Genentech; cobimetinib (at that time XL-518) was part of this collaboration. Exelixis had filed an IND on XL-518 prior to the partnership, committed to funding and running the Phase I trial, and retained rights to co-market it in the US.
In 2008, the company partnered its lead cancer drug candidate, XL-184 (which would become called cabozantinib) and another cancer candidate, XL-281, with Bristol Myers Squibb; BMS returned the rights to XL-184 to Exelixis in 2010 and returned the rights to other drug candidate in 2011.
In 2010, Scangos departed as CEO to take over at Biogen and the company appointed Michael M. Morrissey as president and CEO; Morrissey had joined the company in 2000 as Vice President of Discovery Research. At that time the company had eight drugs in clinical trials.
Exelixis' first drug approval came in 2012, when cabozantinib was approved for medullary thyroid cancer, an orphan indication. It was approved in Europe in 2014.
Exelixis invested heavily in exploring cabozantinib in other cancers, betting the future of the company on the drug. In 2014 the drug failed a Phase III trial in prostate cancer, and the company laid off 70% of its employees.
In 2015, Genentech and Exelixis won FDA approval for cobimetinib for certain forms of melanoma.
In March 2016, Exelixis licensed to Ipsen worldwide rights (outside the US, Canada, and Japan) to market cabozantinib.
In April 2016, the FDA granted approval for marketing the tablet formulation as a second line treatment for kidney cancer and the same was approved in Europe in October of that year.
In December 2017, the FDA granted approval for the use of cabozantinib for first line treatment of kidney cancer and in 2018 approval for first-line treatment was approved in Europe.
Finance
Pricing
Cabometyx (cabozantinib)
In 2023, the Institute for Clinical and Economic Review (ICER) identified Cabometyx (cabozantinib) as one of five high-expenditure drugs that experienced significant net price increases without new clinical evidence to justify the hikes. Specifically, Cabometyx's wholesale acquisition cost rose by 7.5%, leading to an additional $86 million in costs to U.S. payers.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
EXEL Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$54.24
Capitalización Bursátil
$13.76B
P/E (TTM)
18.9
BPA (TTM)
$2.78
Ingresos (TTM)
$2.32B
Rendimiento div.
—
ROE
37.3%
Deuda/Capital
—
Rango 52S
$34 – $58
EXEL Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$2.32B
2016-12-31
→
2026-01-02
BPA
$2.78
2017-12-29
→
2026-01-02
Flujo de caja libre
$876M
2017-12-29
→
2026-01-02
Márgenes
33.7%
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
EXEL
Mediana de Pares
P/E (TTM)
18.9
28.5
P/S (TTM) (P/V (TTM))
5.9
20.1
P/B (P/C)
6.4
12.9
Price / FCF (Precio / FCF)
15.7
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
EXEL
Mediana de Pares
Operating Margin (Margen Operativo)
37.6%
—
Net Profit Margin (Margen de Beneficio Neto)
33.7%
-48.4%
ROA
27.0%
-28.4%
ROE
37.3%
-49.2%
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
EXEL
Mediana de Pares
Current Ratio (Ratio corriente)
3.6
5.0
Quick Ratio (Ratio Rápido)
3.3
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
EXEL
Mediana de Pares
Revenue YoY (Ingresos interanuales)
7.0%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
12.9%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
18.6%
—
EPS YoY (EPS interanual)
58.0%
—
Net Income YoY (Beneficio Neto interanual)
50.1%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
EXEL
Mediana de Pares
EXEL Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
26 analistas
- Compra fuerte 5 19,2%
- Compra 8 30,8%
- Mantener 12 46,2%
- Venta 1 3,8%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
16 analistas · 2026-08-13
Mediana
$52.00
Ahora
$54.24
Mín
$41.00
Máx
$66.00
Objetivo mediano
$52.00
-4,1%
Objetivo medio
$52.94
-2,4%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
0.08%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $0.82 | $0.80 | 0.02% |
| 31 de marzo de 2026 | $0.79 | $0.72 | 0.07% |
| 31 de diciembre de 2025 | $0.88 | $0.82 | 0.06% |
| 30 de septiembre de 2025 | $0.69 | $0.63 | 0.06% |
| 30 de junio de 2025 | $0.65 | $0.57 | 0.08% |
| 31 de marzo de 2025 | $0.55 | $0.37 | 0.18% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 16
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B | $988M | $968M | $854M | $452M | $191M | $37M | |
| Cost of Revenue | $84M | $76M | $73M | $58M | $53M | $36M | $33M | $26M | $15M | $7M | $4M | |
| R&D Expense | $825M | $910M | $1.04B | $892M | $694M | $548M | $337M | $182M | $112M | $96M | $96M | |
| SG&A Expense | $519M | $492M | $543M | $460M | $402M | $293M | $228M | $206M | $159M | $116M | $57M | |
| Operating Expenses | $1.45B | $1.56B | $1.66B | $1.41B | $1.15B | $877M | $598M | $415M | $287M | $220M | $159M | |
| Operating Income | $872M | $605M | $171M | $201M | $287M | $110M | $369M | $439M | $166M | $-28M | $-121M | |
| Interest Expense | · | · | · | · | · | · | $0 | $0 | $9M | $33M | $41M | |
| Other Non-op | $-198.0K | $-133.0K | $93.0K | $-197.0K | $-184.0K | $912.0K | $680.0K | $397.0K | $-4M | $5M | $-381.0K | |
| Pretax Income | · | · | · | · | · | $131M | $398M | $452M | $159M | $-70M | $-162M | |
| Income Tax | $159M | $160M | $50M | $52M | $63M | $19M | $77M | $-238M | $4M | $0 | $55.0K | |
| Net Income | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | $-70M | $-162M | |
| EPS (Basic) | $2.88 | $1.80 | $0.65 | $0.57 | $0.73 | $0.36 | $1.06 | $2.32 | $0.52 | · | $-0.77 | |
| EPS (Diluted) | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 | $0.35 | $1.02 | $2.21 | $0.49 | · | $-0.77 | |
| Shares (Basic) | 271,567,000 | 290,030,000 | 318,151,000 | 321,526,000 | 314,884,000 | 308,271,000 | 302,584,000 | 297,892,000 | 293,588,000 | · | 209,227,000 | |
| Shares (Diluted) | 281,863,000 | 296,132,000 | 321,464,000 | 324,556,000 | 322,359,000 | 318,001,000 | 315,009,000 | 312,803,000 | 312,003,000 | · | 209,227,000 | |
| EBITDA | $901M | $633M | $197M | $222M | $300M | $119M | $378M | $444M | $167M | · | · |
Balance general 27
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $482M | $217M | $263M | $501M | $647M | $319M | $267M | $315M | $183M | $152M | $142M | |
| Short-term Investments | $577M | $894M | $732M | $807M | $820M | $887M | $586M | $379M | $205M | $268M | · | |
| Receivables | $287M | $265M | $237M | $215M | $283M | $161M | $119M | $163M | $77M | $40M | · | |
| Inventory | $22M | $22M | $17M | $33M | $27M | $21M | $13M | $10M | $7M | $3M | · | |
| Prepaid Expense | $76M | $68M | $68M | $62M | $58M | $57M | $27M | $31M | $9M | $5M | · | |
| Current Assets | $1.44B | $1.47B | $1.32B | $1.62B | $1.83B | $1.45B | $1.01B | $897M | $485M | $469M | · | |
| PP&E (Net) | $99M | $119M | $129M | $111M | $104M | $67M | $49M | $51M | $26M | $2M | · | |
| PP&E (Gross) | $231M | $220M | $209M | $171M | $145M | $102M | $74M | $68M | $49M | $27M | · | |
| Accum. Depreciation | $132M | $101M | $80M | $61M | $41M | $35M | $26M | $17M | $23M | $25M | · | |
| Goodwill | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | · | |
| Other Non-current Assets | · | · | · | · | $131M | $73M | $53M | $8M | $12M | $1M | · | |
| Total Assets | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B | $2.14B | $1.89B | $1.42B | $655M | $596M | · | |
| Accounts Payable | $30M | $38M | $34M | $33M | $24M | $24M | $12M | $11M | $10M | $7M | · | |
| Short-term Debt | · | · | · | · | · | · | · | · | $0 | $80M | · | |
| Current Liabilities | $406M | $404M | $394M | $324M | $338M | $205M | $143M | $105M | $115M | $269M | · | |
| Capital Leases | $173M | $191M | $190M | $190M | $51M | $49M | $48M | $12M | $15M | · | · | |
| Other Non-current Liabilities | $104M | $109M | $94M | $69M | $8M | $721.0K | $2M | $1M | $2M | $541.0K | · | |
| Total Liabilities | $683M | $703M | $678M | $583M | $406M | $258M | $200M | $135M | $370M | $506M | · | |
| Long-term Debt | · | · | · | · | · | · | · | · | $0 | $189M | · | |
| Total Debt | · | · | · | · | · | · | · | · | $0 | · | · | |
| Common Stock | $262.0K | $282.0K | $303.0K | $324.0K | $319.0K | $312.0K | $305.0K | $300.0K | $296.0K | $290.0K | · | |
| Paid-in Capital | $2.23B | $2.34B | $2.44B | $2.54B | $2.43B | $2.32B | $2.24B | $2.17B | $2.11B | $2.07B | · | |
| Retained Earnings | $-77M | $-99M | $-173M | $-34M | $-217M | $-448M | $-559M | $-880M | $-1.83B | $-1.98B | · | |
| AOCI | $3M | $-1M | $-4M | $-15M | $-758.0K | $4M | $3M | $-701.0K | $-347.0K | $-416.0K | · | |
| Stockholders' Equity | $2.16B | $2.24B | $2.26B | $2.49B | $2.21B | $1.88B | $1.69B | $1.29B | $285M | $89M | $-141M | |
| Liabilities + Equity | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B | $2.14B | $1.89B | $1.42B | $655M | $596M | · | |
| Shares Outstanding | 262,483,000 | 281,732,000 | 302,793,000 | 323,951,000 | 318,842,000 | 311,627,000 | 304,831,000 | 299,876,000 | 296,209,000 | 289,923,798 | 227,960,943 |
Flujo de Efectivo 17
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $29M | $29M | $26M | $21M | $14M | $9M | $8M | $5M | $1M | $1M | $1M | |
| Stock-based Comp | $113M | $94M | $106M | $108M | $120M | $105M | $57M | $41M | $24M | $23M | $22M | |
| Deferred Tax | $126M | $-59M | $-133M | $-60M | $47M | $15M | $71M | $-244M | $0 | $0 | $0 | |
| Restructuring | $21M | $34M | $0 | $0 | · | · | · | $0 | $-32.0K | $63M | $1M | |
| Other Non-cash | $-167M | $116M | $127M | $112M | $-10M | $-32M | $70M | $-76M | $-14M | · | · | |
| Operating Cash Flow | $884M | $700M | $333M | $363M | $401M | $209M | $527M | $416M | $166M | $206M | $-141M | |
| CapEx | $8M | $28M | $40M | $28M | $54M | $30M | $13M | $33M | $21M | $2M | $447.0K | |
| Investing Cash Flow | $350M | $-117M | $-27M | $-524M | $-43M | $-131M | $-587M | $-298M | $37M | $-216M | $50M | |
| Net Debt Issued | · | · | · | · | · | · | $0 | $0 | $-186M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | $0 | $0 | $146M | |
| Stock Repurchased | $948M | $652M | $550M | $0 | $0 | · | · | · | · | · | · | |
| Net Stock Activity | $-948M | $-652M | $-550M | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $-970M | $-629M | $-546M | $586.0K | $-15M | $-25M | $13M | $10M | $-170M | $20M | $152M | |
| Net Change in Cash | $265M | $-46M | $-240M | $-161M | $343M | $53M | $-48M | $128M | $32M | $10M | $61M | |
| Taxes Paid | $155M | $170M | $186M | $128M | $13M | $4M | $8M | $11M | $538.0K | · | · | |
| Free Cash Flow | $876M | $672M | $293M | $335M | $337M | $179M | $514M | $382M | $144M | · | · | |
| Levered FCF | · | · | · | · | · | · | $514M | $382M | $136M | · | · |
Rentabilidad 7
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | 11.1% | 38.2% | 51.4% | 36.7% | · | · | |
| Net Margin | 33.7% | 24.0% | 11.3% | 11.3% | 16.1% | 11.3% | 33.2% | 80.8% | 34.1% | · | · | |
| Pretax Margin | · | · | · | · | · | 13.2% | 41.1% | 52.9% | 35.0% | · | · | |
| EBITDA Margin | 38.8% | 29.2% | 10.7% | 13.8% | 20.9% | 12.1% | 39.0% | 52.0% | 36.9% | · | · | |
| ROA | 27.0% | 17.7% | 6.9% | 6.4% | 9.7% | 5.6% | 19.4% | 66.4% | 24.7% | · | · | |
| ROE | 37.3% | 23.1% | 9.0% | 7.3% | 10.7% | 6.0% | 19.5% | 62.6% | 82.4% | · | · | |
| ROIC | · | · | · | · | · | 5.0% | 17.7% | 52.0% | 56.6% | · | · |
Liquidez y Solvencia 4
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | 3.6 | 3.3 | 5.0 | 5.4 | 7.1 | 7.1 | 8.5 | 4.2 | · | · | |
| Quick Ratio | 3.3 | 3.4 | 3.1 | 4.7 | 5.2 | 6.7 | 6.8 | 8.1 | 4.1 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 0.0 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 19.1 | · | · |
Eficiencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.7 | 0.6 | 0.6 | 0.6 | 0.5 | 0.6 | 0.8 | 0.7 | · | · | |
| Inventory Turnover | 3.8 | 3.8 | 2.9 | 1.9 | 2.2 | 2.1 | 2.9 | 3.2 | 3.0 | · | · | |
| Receivables Turnover | 8.4 | 8.6 | 8.1 | 6.5 | 6.5 | 7.1 | 6.9 | 9.8 | 7.4 | · | · |
Tasas de Crecimiento 9
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.0% | 18.5% | 13.6% | 12.3% | 45.3% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 12.9% | 14.8% | 22.8% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 18.6% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 58.0% | 170.8% | 16.1% | -22.2% | 105.7% | · | · | · | · | · | · | |
| EPS CAGR 3Y | 70.6% | 34.7% | 22.9% | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 51.3% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 50.1% | 150.9% | 14.0% | -21.1% | 106.7% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 62.5% | 31.1% | 22.9% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 47.6% | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 14
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B | $988M | $968M | $854M | $452M | · | $37M | |
| Net Income TTM | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | · | $-162M | |
| Market Cap | $11.44B | $9.57B | $7.26B | $5.20B | $5.83B | $6.25B | $5.19B | $5.83B | $9.00B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $8.62B | · | · | |
| P/E | 15.7 | 19.3 | 36.9 | 28.6 | 25.4 | 57.3 | 16.7 | 8.8 | 62.0 | · | -7.3 | |
| P/S | 4.9 | 4.4 | 4.0 | 3.2 | 4.1 | 6.3 | 5.4 | 6.8 | 19.9 | · | · | |
| P/B | 5.3 | 4.3 | 3.2 | 2.1 | 2.6 | 3.3 | 3.1 | 4.5 | 31.6 | · | · | |
| P / Tangible Book | 5.5 | 4.4 | 3.3 | 2.1 | 2.7 | 3.4 | · | · | · | · | · | |
| P / Cash Flow | 12.9 | 13.7 | 21.8 | 14.3 | 14.5 | 29.9 | 9.8 | 14.0 | 54.4 | · | · | |
| P / FCF | 13.1 | 14.3 | 24.8 | 15.5 | 17.3 | 35.0 | 10.1 | 15.2 | 62.3 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | 51.6 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | 59.6 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 19.0 | · | · | |
| Earnings Yield | 6.4% | 5.2% | 2.7% | 3.5% | 3.9% | 1.7% | 6.0% | 11.4% | 1.6% | · | -13.7% |
Estado de resultados 14
| Métrica | Tendencia | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $629M | $611M | $718M | $598M | $568M | $555M | $818M | $540M | $637M | $425M | $480M | $472M | $470M | $409M | $424M | $412M | |
| Cost of Revenue | $21M | $20M | $27M | $19M | $19M | $19M | $25M | $17M | $18M | $21M | $22M | $19M | $18M | $14M | $16M | $15M | |
| R&D Expense | $212M | $200M | $164M | $199M | $200M | $212M | $111M | $223M | $211M | $228M | $245M | $333M | $233M | $234M | $337M | $199M | |
| SG&A Expense | $148M | $140M | $161M | $124M | $135M | $137M | $81M | $112M | $132M | $114M | $131M | $138M | $142M | $131M | $119M | $115M | |
| Operating Expenses | $380M | $359M | $287M | $361M | $355M | $369M | $303M | $403M | $361M | $396M | $398M | $490M | $392M | $380M | $472M | $329M | |
| Operating Income | $248M | $251M | $431M | $237M | $214M | $187M | $516M | $136M | $276M | $29M | $82M | $-18M | $78M | $29M | $-48M | $83M | |
| Other Non-op | $54.0K | $219.0K | $207.0K | $-49.0K | $50.0K | $-245.0K | $-363.0K | $-29.0K | $-287.0K | $-89.0K | $-137.0K | $289.0K | $-5.0K | $-54.0K | $-337.0K | $-69.0K | |
| Income Tax | $51M | $57M | $43M | $59M | $46M | $46M | $128M | $37M | $67M | $12M | $18M | $5M | $19M | $8M | $-1M | $19M | |
| Net Income | $212M | $210M | $401M | $194M | $185M | $160M | $399M | $118M | $226M | $37M | $86M | $1M | $81M | $40M | $-30M | $73M | |
| EPS (Basic) | $0.85 | $0.81 | $1.57 | $0.72 | $0.68 | $0.57 | $1.43 | $0.41 | $0.78 | $0.12 | $0.28 | $0.00 | $0.25 | $0.12 | $-0.09 | $0.23 | |
| EPS (Diluted) | $0.82 | $0.79 | $1.49 | $0.69 | $0.65 | $0.55 | $1.39 | $0.40 | $0.77 | $0.12 | $0.28 | $0.00 | $0.25 | $0.12 | $-0.09 | $0.23 | |
| Shares (Basic) | 250,808,000 | 258,329,000 | -604,028,000 | 268,421,000 | 272,583,000 | 278,804,000 | -674,091,000 | 285,622,000 | 289,216,000 | 300,757,000 | -645,970,000 | 315,496,000 | 324,205,000 | 324,420,000 | 577,000 | 322,148,000 | |
| Shares (Diluted) | 259,675,000 | 267,322,000 | -609,119,000 | 278,535,000 | 284,393,000 | 288,177,000 | -676,699,000 | 291,478,000 | 293,974,000 | 305,530,000 | -651,367,000 | 319,247,000 | 327,305,000 | 326,279,000 | 136,000 | 325,066,000 | |
| EBITDA | $248M | $258M | · | $237M | $214M | $194M | · | $136M | $276M | $36M | · | $-18M | $78M | $36M | · | $83M |
Balance general 24
| Métrica | Tendencia | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $281M | $226M | $482M | $376M | $164M | $184M | $217M | $258M | $198M | $260M | · | $397M | $464M | $541M | · | $675M | |
| Short-term Investments | $558M | $551M | $577M | $612M | $627M | $848M | $894M | $931M | $804M | $704M | · | $707M | $802M | $773M | · | $872M | |
| Receivables | $322M | $329M | $287M | $310M | $292M | $282M | $265M | $270M | $397M | $241M | · | $248M | $233M | $234M | · | $215M | |
| Inventory | $29M | $27M | $22M | $27M | $23M | $25M | $22M | $21M | $21M | $21M | · | $25M | $29M | $30M | · | $27M | |
| Prepaid Expense | $60M | $76M | $76M | $77M | $74M | $59M | $68M | $70M | $58M | $67M | · | $67M | $62M | $61M | · | $53M | |
| Current Assets | $1.25B | $1.21B | $1.44B | $1.40B | $1.18B | $1.40B | $1.47B | $1.55B | $1.48B | $1.29B | · | $1.44B | $1.59B | $1.64B | · | $1.84B | |
| PP&E (Net) | $93M | $96M | $99M | $105M | $110M | $115M | $119M | $124M | $130M | $127M | · | $121M | $115M | $116M | · | $108M | |
| PP&E (Gross) | · | · | $231M | · | · | · | $220M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $132M | · | · | · | $101M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | · | $64M | $64M | $64M | · | $64M | |
| Other Non-current Assets | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $280M | |
| Total Assets | $2.49B | $2.59B | $2.84B | $2.82B | $2.68B | $2.84B | $2.95B | $2.96B | $2.77B | $2.80B | · | $2.98B | $3.14B | $3.14B | · | $2.96B | |
| Accounts Payable | $39M | $24M | $30M | $25M | $26M | $43M | $38M | $59M | $29M | $26M | · | $26M | $26M | $33M | · | $31M | |
| Current Liabilities | $362M | $371M | $406M | $374M | $336M | $399M | $404M | $394M | $346M | $373M | · | $377M | $340M | $328M | · | $302M | |
| Capital Leases | $166M | $170M | $173M | $176M | $180M | $187M | $191M | $194M | $198M | $201M | · | $191M | $195M | $187M | · | $160M | |
| Other Non-current Liabilities | $123M | $117M | $104M | $113M | $129M | $120M | $109M | $96M | $110M | $101M | · | $62M | $73M | $67M | · | $2M | |
| Total Liabilities | $650M | $658M | $683M | $663M | $645M | $706M | $703M | $685M | $653M | $676M | · | $629M | $615M | $588M | · | $470M | |
| Common Stock | $249.0K | $254.0K | $262.0K | $268.0K | $270.0K | $275.0K | $282.0K | $286.0K | $285.0K | $295.0K | · | $311.0K | $320.0K | $325.0K | · | $323.0K | |
| Paid-in Capital | $2.11B | $2.15B | $2.23B | $2.26B | $2.25B | $2.29B | $2.34B | $2.36B | $2.32B | $2.39B | · | $2.49B | $2.53B | $2.56B | · | $2.51B | |
| Retained Earnings | $-263M | $-216M | $-77M | $-106M | $-220M | $-163M | $-99M | $-90M | $-200M | $-259M | · | $-126M | $11M | $6M | · | $-4M | |
| AOCI | $-2M | $-415.0K | $3M | $4M | $1M | $2M | $-1M | $4M | $-5M | $-5M | · | $-14M | $-14M | $-9M | · | $-18M | |
| Stockholders' Equity | $1.84B | $1.94B | $2.16B | $2.16B | $2.03B | $2.13B | $2.24B | $2.28B | $2.12B | $2.13B | $2.26B | $2.35B | $2.53B | $2.56B | $2.49B | $2.49B | |
| Liabilities + Equity | $2.49B | $2.59B | $2.84B | $2.82B | $2.68B | $2.84B | $2.95B | $2.96B | $2.77B | $2.80B | · | $2.98B | $3.14B | $3.14B | · | $2.96B | |
| Shares Outstanding | 248,885,000 | 253,701,000 | 262,483,000 | 268,098,000 | 270,132,000 | 275,033,000 | 281,732,000 | 285,780,000 | 285,222,000 | 295,032,000 | 302,793,000 | 310,970,000 | 320,253,000 | 324,985,000 | 323,951,000 | 322,541,000 |
Flujo de Efectivo 12
| Métrica | Tendencia | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $7M | $8M | $7M | $7M | $7M | $10M | $7M | $7M | $6M | $7M | $6M | $6M | $7M | $6M | $6M | |
| Stock-based Comp | $33M | $29M | $45M | $31M | $36M | $26M | $12M | $23M | $25M | $19M | $24M | $40M | $25M | $17M | $26M | $37M | |
| Restructuring | · | · | $-13M | $20M | $0 | $0 | $34M | $96.0K | $475.0K | $33M | · | $0 | $0 | $0 | · | · | |
| Other Non-cash | · | $5M | · | · | · | $19M | · | · | · | $6M | · | · | · | $21M | · | · | |
| Operating Cash Flow | $308M | $252M | $425M | $290M | $49M | $211M | $377M | $271M | $120M | $69M | $11M | $117M | $121M | $84M | $74M | $110M | |
| CapEx | $7M | $2M | $-16M | $1M | $3M | $3M | $1M | $8M | $7M | $10M | $13M | $9M | $6M | $12M | $10M | $43.0K | |
| Investing Cash Flow | $91M | $-51M | $374M | $25M | $248M | $50M | $-28M | $-217M | $82M | $112M | $62M | $35M | $-74M | $-50M | $-246M | $-69M | |
| Stock Repurchased | $323M | $430M | $486M | $104M | $302M | $284M | $311M | $12M | $264M | $185M | $209M | $217M | $124M | $0 | $0 | $0 | |
| Net Stock Activity | · | $-430M | · | · | · | $-284M | · | · | · | $-185M | · | · | · | · | · | · | |
| Financing Cash Flow | $-344M | $-457M | $-529M | $-104M | $-316M | $-295M | $-289M | $6M | $-262M | $-184M | $-206M | $-220M | $-125M | $5M | $-2M | $-2M | |
| Net Change in Cash | $55M | $-256M | $270M | $212M | $-19M | $-34M | $60M | $60M | $-61M | $-3M | $-134M | $-68M | $-78M | $39M | $-174M | $39M | |
| Free Cash Flow | · | $250M | · | · | · | $208M | · | · | · | $59M | · | · | · | $72M | · | · |
Rentabilidad 5
| Métrica | Tendencia | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.5% | 41.1% | · | 39.6% | 37.6% | 33.6% | · | 25.2% | 43.3% | 6.9% | · | -3.7% | 16.6% | 7.0% | · | 20.1% | |
| Net Margin | 33.7% | 34.5% | · | 32.4% | 32.5% | 28.7% | · | 21.9% | 35.5% | 8.8% | · | 0.22% | 17.3% | 9.8% | · | 17.8% | |
| EBITDA Margin | 39.5% | 42.3% | · | 39.6% | 37.6% | 35.0% | · | 25.2% | 43.3% | 8.4% | · | -3.7% | 16.6% | 8.7% | · | 20.1% | |
| ROA | 8.2% | 7.8% | · | 6.7% | 6.8% | 5.7% | · | 4.0% | 7.6% | 1.2% | · | 0.04% | 2.7% | 1.4% | · | 2.7% | |
| ROE | 10.9% | 10.3% | · | 8.7% | 8.9% | 7.5% | · | 5.1% | 9.7% | 1.6% | · | 0.04% | 3.3% | 1.7% | · | 3.2% |
Liquidez y Solvencia 2
| Métrica | Tendencia | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.3 | · | 3.8 | 3.5 | 3.5 | · | 3.9 | 4.3 | 3.5 | · | 3.8 | 4.7 | 5.0 | · | 6.1 | |
| Quick Ratio | 3.2 | 3.0 | · | 3.5 | 3.2 | 3.3 | · | 3.7 | 4.0 | 3.2 | · | 3.6 | 4.4 | 4.7 | · | 5.8 |
Eficiencia 3
| Métrica | Tendencia | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.8 | · | 0.8 | 0.7 | 0.8 | · | 0.7 | 0.6 | 0.5 | · | 0.6 | |
| Receivables Turnover | 2.0 | 2.0 | · | 2.1 | 1.6 | 2.1 | · | 2.1 | 2.0 | 1.8 | · | 2.0 | 2.0 | 1.9 | · | 2.1 |
Valoración (TTM) 10
| Métrica | Tendencia | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.41B | $2.33B | · | $2.26B | $2.30B | $2.16B | · | $2.07B | $2.00B | $1.78B | · | $1.76B | $1.71B | $1.60B | · | $1.52B | |
| Net Income TTM | $801M | $749M | · | $656M | $689M | $541M | · | $382M | $346M | $160M | · | $195M | $265M | $252M | · | $251M | |
| Market Cap | $13.90B | $11.13B | · | $10.75B | $12.47B | $9.51B | · | $7.42B | $6.41B | $7.00B | · | $6.79B | $6.12B | $6.31B | · | $5.06B | |
| P/E | 18.9 | 16.4 | · | 17.5 | 19.5 | 18.8 | · | 20.1 | 19.7 | 48.4 | · | 36.4 | 23.3 | 24.9 | · | 20.1 | |
| P/S | 5.8 | 4.8 | · | 4.8 | 5.4 | 4.4 | · | 3.6 | 3.2 | 3.9 | · | 3.9 | 3.6 | 4.0 | · | 3.3 | |
| P/B | 7.5 | 5.8 | · | 5.0 | 6.1 | 4.5 | · | 3.3 | 3.0 | 3.3 | · | 2.9 | 2.4 | 2.5 | · | 2.0 | |
| P / Tangible Book | 7.8 | 5.9 | · | 5.1 | 6.3 | 4.6 | · | 3.4 | 3.1 | 3.4 | · | 3.0 | 2.5 | 2.5 | · | 2.1 | |
| P / Cash Flow | · | 44.2 | · | · | · | 45.0 | · | · | · | 101.7 | · | · | · | 74.7 | · | · | |
| P / FCF | · | 44.5 | · | · | · | 45.6 | · | · | · | 118.4 | · | · | · | 87.1 | · | · | |
| Earnings Yield | 5.3% | 6.1% | · | 5.7% | 5.1% | 5.3% | · | 5.0% | 5.1% | 2.1% | · | 2.8% | 4.3% | 4.0% | · | 5.0% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B |
| Margen Operativo % | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% |
| Beneficio neto | $783M | $521M | $208M | $182M | $231M |
| EPS Diluido | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 |
Balance general
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio corriente | 3.6 | 3.6 | 3.3 | 5.0 | 5.4 |
| Ratio Rápido | 3.3 | 3.4 | 3.1 | 4.7 | 5.2 |
Flujo de Efectivo
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $876M | $672M | $293M | $335M | $337M |
Últimas noticias Noticias recientes que mencionan a esta empresa
Señales de trading Señales recientes de compra/venta con precio de entrada y ratio riesgo/recompensa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 811 declarantes · $9.1B total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 135 (+27 vs trimestre anterior) | 61 (-13 vs trimestre anterior) | 240 (-1 vs trimestre anterior) | 274 (+16 vs trimestre anterior) | +39.8M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $732 794 424 | 13 468 010 | 8,04% | Acciones |
| RENAISSANCE TECHNOLOGIES LLC | $730 617 099 | 13 427 993 | 8,01% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $655 266 268 | 12 043 122 | 7,19% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $595 843 747 | 10 950 997 | 6,53% | Acciones |
| STATE STREET CORP | $542 471 563 | 9 970 071 | 5,95% | Acciones |
| FULLER & THALER ASSET MANAGEMENT, INC. | $485 848 030 | 8 929 389 | 5,33% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $362 702 104 | 6 664 894 | 3,98% | Acciones |
| D. E. Shaw & Co., Inc. | $281 389 313 | 5 171 647 | 3,09% | Acciones |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $237 550 034 | 4 365 926 | 2,60% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $229 058 537 | 4 209 861 | 2,51% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $221 832 835 | 4 077 060 | 2,43% | Acciones |
| ASSETMARK, INC | $186 834 364 | 3 433 824 | 2,05% | Acciones |
| Stephens Investment Management Group LLC | $147 451 698 | 2 710 011 | 1,62% | Acciones |
| NORGES BANK | $146 301 199 | 2 688 866 | 1,60% | Acciones |
| FIRST TRUST ADVISORS LP | $138 383 701 | 2 543 353 | 1,52% | Acciones |
| Caisse de depot et placement du Quebec | $113 950 809 | 2 094 299 | 1,25% | Acciones |
| GOLDMAN SACHS GROUP INC | $106 578 308 | 1 958 800 | 1,17% | Acciones |
| AMERICAN CENTURY COMPANIES INC | $97 484 439 | 1 791 664 | 1,07% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $86 563 209 | 1 590 943 | 0,95% | Acciones |
| Caligan Partners LP | $84 512 985 | 1 553 262 | 0,93% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $66 309 793 | 1 218 706 | 0,73% | Acciones |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $63 086 055 | 1 159 457 | 0,69% | Acciones |
| BANK OF AMERICA CORP /DE/ | $58 788 318 | 1 080 469 | 0,64% | Acciones |
| Robeco Institutional Asset Management B.V. | $56 032 453 | 1 029 819 | 0,61% | Acciones |
| ENVESTNET ASSET MANAGEMENT INC | $51 671 488 | 949 669 | 0,57% | Acciones |
| FMR LLC | $48 839 667 | 897 623 | 0,54% | Acciones |
| Gotham Asset Management, LLC | $48 569 794 | 892 663 | 0,53% | Acciones |
| Swedbank AB | $45 801 141 | 841 778 | 0,50% | Acciones |
| Allspring Global Investments Holdings, LLC | $44 544 520 | 825 510 | 0,49% | Acciones |
| Retirement Systems of Alabama | $44 107 739 | 810 655 | 0,48% | Acciones |
| BOOTHBAY FUND MANAGEMENT, LLC | $43 750 809 | 804 095 | 0,48% | Acciones |
| RAYMOND JAMES FINANCIAL INC | $41 924 320 | 770 526 | 0,46% | Acciones |
| Capital Impact Advisors, LLC | $41 061 268 | 754 664 | 0,45% | Acciones |
| BlackRock, Inc. | $40 753 525 | 749 008 | 0,45% | Acciones |
| RHUMBLINE ADVISERS | $35 723 294 | 656 559 | 0,39% | Acciones |
| CANADA PENSION PLAN INVESTMENT BOARD | $35 464 438 | 651 800 | 0,39% | Acciones |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $34 721 830 | 639 680 | 0,38% | Acciones |
| MARSHALL WACE, LLP | $34 322 590 | 630 814 | 0,38% | Acciones |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $34 315 027 | 630 675 | 0,38% | Acciones |
| AMERIPRISE FINANCIAL INC | $32 255 716 | 592 827 | 0,35% | Acciones |
| BARCLAYS PLC | $31 502 574 | 578 985 | 0,35% | Acciones |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $31 496 480 | 578 873 | 0,35% | Acciones |
| Arbejdsmarkedets Tillaegspension | $30 855 911 | 567 100 | 0,34% | Acciones |
| Pictet Asset Management Holding SA | $30 153 926 | 555 438 | 0,33% | Acciones |
| California Public Employees Retirement System | $29 366 600 | 539 728 | 0,32% | Acciones |
| CAPITAL FUND MANAGEMENT S.A. | $28 686 856 | 527 235 | 0,31% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $28 655 734 | 526 663 | 0,31% | Acciones |
| JANUS HENDERSON GROUP PLC | $26 675 806 | 621 814 | 0,29% | Acciones |
| Woodline Partners LP | $26 411 049 | 485 408 | 0,29% | Acciones |
| Driehaus Capital Management LLC | $26 025 500 | 478 322 | 0,29% | Acciones |
| EULAV Asset Management | $25 901 500 | 476 043 | 0,28% | Acciones |
| Squarepoint Ops LLC | $25 774 398 | 473 707 | 0,28% | Acciones |
| Swiss National Bank | $25 648 874 | 471 400 | 0,28% | Acciones |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $25 156 355 | 462 348 | 0,28% | Acciones |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24 600 555 | 452 133 | 0,27% | Acciones |
| IEQ CAPITAL, LLC | $24 580 697 | 451 768 | 0,27% | Acciones |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $23 831 580 | 438 000 | 0,26% | Acciones |
| Baird Financial Group, Inc. | $23 565 461 | 433 109 | 0,26% | Acciones |
| FRANKLIN RESOURCES INC | $23 480 472 | 431 547 | 0,26% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23 347 331 | 429 100 | 0,26% | Opción de compra |
| Assenagon Asset Management S.A. | $23 324 098 | 428 673 | 0,26% | Acciones |
| BANK OF NOVA SCOTIA | $22 837 676 | 419 730 | 0,25% | Acciones |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $22 615 516 | 415 650 | 0,25% | Acciones |
| South Street Advisors LLC | $22 275 019 | 409 392 | 0,24% | Acciones |
| Bridgewater Associates, LP | $21 810 738 | 400 859 | 0,24% | Acciones |
| VICTORY CAPITAL MANAGEMENT INC | $21 480 143 | 394 783 | 0,24% | Acciones |
| ROYAL BANK OF CANADA | $20 031 000 | 368 153 | 0,22% | Acciones |
| SEI INVESTMENTS CO | $19 897 640 | 365 698 | 0,22% | Acciones |
| LAZARD ASSET MANAGEMENT LLC | $18 664 208 | 343 029 | 0,20% | Acciones |
| Nuveen, LLC | $18 299 226 | 336 321 | 0,20% | Acciones |
| Nuveen Asset Management, LLC | $18 252 629 | 548 127 | 0,20% | Acciones |
| NFJ INVESTMENT GROUP, LLC | $17 880 160 | 328 619 | 0,20% | Acciones |
| SAWGRASS ASSET MANAGEMENT LLC | $17 808 447 | 327 301 | 0,20% | Acciones |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $17 565 616 | 322 838 | 0,19% | Acciones |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $17 472 485 | 407 379 | 0,19% | Acciones |
| ING GROEP NV | $16 943 274 | 311 400 | 0,19% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $16 529 758 | 303 800 | 0,18% | Opción de venta |
| Brandywine Global Investment Management, LLC | $16 490 117 | 376 229 | 0,18% | Acciones |
| CAPTRUST FINANCIAL ADVISORS | $16 488 532 | 303 042 | 0,18% | Acciones |
| INTECH INVESTMENT MANAGEMENT LLC | $16 262 224 | 298 883 | 0,18% | Acciones |
| HighTower Advisors, LLC | $15 842 121 | 291 162 | 0,17% | Acciones |
| SEIZERT CAPITAL PARTNERS, LLC | $15 411 796 | 283 253 | 0,17% | Acciones |
| Trexquant Investment LP | $14 974 122 | 275 209 | 0,16% | Acciones |
| Clark Capital Management Group, Inc. | $14 792 882 | 271 878 | 0,16% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $14 763 381 | 344 215 | 0,16% | Acciones |
| VAN ECK ASSOCIATES CORP | $14 270 709 | 262 281 | 0,16% | Acciones |
| GLOBEFLEX CAPITAL L P | $13 874 169 | 254 993 | 0,15% | Acciones |
| Sofinnova Investments, Inc. | $13 831 022 | 254 200 | 0,15% | Opción de venta |
| JANE STREET GROUP, LLC | $13 815 570 | 253 916 | 0,15% | Acciones |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $13 724 052 | 252 234 | 0,15% | Acciones |
| Voleon Capital Management LP | $13 682 047 | 251 462 | 0,15% | Acciones |
| BLAIR WILLIAM & CO/IL | $13 233 352 | 243 215 | 0,15% | Acciones |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $13 027 000 | 239 418 | 0,14% | Acciones |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12 745 021 | 297 156 | 0,14% | Acciones |
| MERITAGE PORTFOLIO MANAGEMENT | $12 679 099 | 289 279 | 0,14% | Acciones |
| VANGUARD ASSET MANAGEMENT, Ltd | $12 516 694 | 230 044 | 0,14% | Acciones |
| Susquehanna Portfolio Strategies, LLC | $12 500 643 | 229 749 | 0,14% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $12 035 492 | 221 200 | 0,13% | Opción de compra |
| Illinois Municipal Retirement Fund | $11 750 764 | 215 967 | 0,13% | Acciones |
| CWM, LLC | $11 300 486 | 263 476 | 0,12% | Acciones |
Informantes de la empresa 43 insiders · 22 directivos · 10 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Michael Morrissey | President and CEO | 18 de mayo de 2026 G | 2 004 327 | 0 | 0 | $0 |
| Christopher J. Senner | EVP and CFO | 18 de mayo de 2026 S | 952 317 | 0 | 3 | $-4 556 048 |
| Deborah Burke | SVP & Chief Financial Officer | 15 de noviembre de 2014 M | 18 156 | 0 | 0 | $0 |
| Frank Karbe | EVP and CFO | 15 de febrero de 2014 M | 93 990 | 0 | 0 | $0 |
| Kristine M Ball | Controller & Interim CFO | 10 de diciembre de 2003 A | 4 913 | 0 | 0 | $0 |
| Patrick J. Haley | EVP, Commercial | 20 de mayo de 2026 S | 357 638 | 0 | 7 | $-7 597 268 |
| Brenda Hefti | SVP and General Counsel | 18 de mayo de 2026 S | 106 762 | 0 | 2 | $-1 154 264 |
| Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | 16 de mayo de 2025 M | 465 393 | 0 | 0 | $0 |
| Jeffrey Hessekiel | EVP & General Counsel | 15 de mayo de 2025 S | 693 396 | 0 | 0 | $0 |
| Vicki L Goodman | EVP, Prod Dev & Med Aff &CMO | 3 de abril de 2023 A | 307 654 | 0 | 0 | $0 |
| Peter Lamb | EVP, Scientific Strategy & CSO | 15 de diciembre de 2022 M | 410 958 | 0 | 0 | $0 |
| Gisela Schwab | Pres, Prod Dev & Med Aff & CMO | 26 de julio de 2021 M | 689 078 | 0 | 0 | $0 |
| Pamela A Simonton | EVP and General Counsel | 15 de noviembre de 2013 M | 17 139 | 0 | 0 | $0 |
| Lupe M Rivera | EVP, Operations | 15 de agosto de 2011 M | 19 219 | 0 | 0 | $0 |
| Frances K Heller | EVP, Business Development | 15 de mayo de 2011 M | 17 125 | 0 | 0 | $0 |
| Ian D Malcolm | VP, STRATEGIC MARKETING | 8 de diciembre de 2006 A | — | 0 | 0 | $0 |
| Christoph Pereira | VP, Legal Affairs & Secretary | 8 de diciembre de 2006 A | — | 0 | 0 | $0 |
| Jeffrey Latts | Executive VP, Development | 8 de diciembre de 2006 A | — | 0 | 0 | $0 |
| Gregory Plowman | Sr VP, CSO | 13 de diciembre de 2004 A | — | 0 | 0 | $0 |
| Steven P James | Sr VP, Commercial Ops | 10 de diciembre de 2003 A | — | 0 | 0 | $0 |
| Jane M Green | VP, Corp Communications | 10 de diciembre de 2003 A | — | 0 | 0 | $0 |
| Geoffrey M Duyk | Pres R&D & CSO | 4 de noviembre de 2003 S | 941 355 | 0 | 0 | $0 |
| Alan M Garber | Consejero | 21 de marzo de 2024 M | 35 703 | 0 | 0 | $0 |
| Jacqueline Wright | Consejero | 1 de junio de 2023 A | 51 756 | 0 | 0 | $0 |
| Carl B Feldbaum | Consejero | 9 de febrero de 2023 M | 18 701 | 0 | 0 | $0 |
| Lance Willsey | Consejero | 26 de mayo de 2022 A | 424 415 | 0 | 0 | $0 |
| Vincent T Marchesi | Consejero | 26 de mayo de 2022 A | 93 989 | 0 | 0 | $0 |
| Charles Cohen | Consejero | 6 de julio de 2021 M | 261 375 | 0 | 0 | $0 |
| George A Scangos | Consejero | 18 de mayo de 2020 S | 714 717 | 0 | 0 | $0 |
| FORMELA JEAN FRANCOIS | Consejero | 7 de septiembre de 2005 S | 584 519 | 0 | 0 | $0 |
| Mary C Beckerle | — | 10 de agosto de 2026 S | 16 079 | 0 | 4 | $-1 932 572 |
| Sue Gail Eckhardt | — | 1 de junio de 2026 S | 16 079 | 0 | 2 | $-660 828 |
| Jack L Wyszomierski | — | 1 de junio de 2026 S | 284 384 | 0 | 2 | $-4 580 661 |
| Tomas J. Heyman | — | 27 de mayo de 2026 A | 50 649 | 0 | 0 | $0 |
| Bob Oliver | — | 27 de mayo de 2026 A | 29 487 | 0 | 2 | $-1 325 340 |
| Julie Smith | — | 27 de mayo de 2026 A | 28 957 | 0 | 3 | $-4 687 346 |
| Maria C Freire | — | 27 de mayo de 2026 A | 109 186 | 0 | 1 | $-949 164 |
| Stelios Papadopoulos | — | 27 de mayo de 2026 A | 1 197 595 | 0 | 1 | $-4 355 000 |
| George Poste | — | 27 de mayo de 2026 A | 127 199 | 0 | 1 | $-2 742 600 |
| Dana Aftab | — | 26 de mayo de 2026 S | 594 741 | 0 | 4 | $-7 701 255 |
| Frank Mccormick | — | 6 de diciembre de 2013 A | — | 0 | 0 | $0 |
| Scott J. Garland | — | 18 de septiembre de 2013 A | — | 0 | 0 | $0 |
| Jason S Fisherman | — | 8 de septiembre de 2005 S | 7 881 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 4 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Farallon Capital Management, L.L.C., Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., Farallon Healthcare Partners Master, L.P., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., Farallon Healthcare Partners (GP), L.L.C., Dapice Joshua J., Dreyfuss, Philip D., Dunn Hannah E., Gehani, Varun N., Giauque, Nicolas, Husen, Avner A., Kim, David T., Linn, Michael G., Luo Patrick (Cheng), Roberts, Jr., Thomas G., Saito Edric C., Short Daniel S., Spokes, Andrew J. M., Warren, John R., Wehrly, Mark C. | 14 de agosto de 2026 | 5,60% | Enmienda | — | SEC |
| Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., Farallon Healthcare Partners Master, L.P., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., Farallon Healthcare Partners (GP), L.L.C., Dapice Joshua J., Dreyfuss, Philip D., Dunn Hannah E., Fried, Richard B, Gehani, Varun N., Giauque, Nicolas, Husen, Avner A., Kim, David T., Linn, Michael G., Luo Patrick (Cheng), Patel, Rajiv A., Roberts, Jr., Thomas G., Saito Edric C., Seybold, William, Short Daniel S., Spokes, Andrew J. M., Warren, John R., Wehrly, Mark C. ×8 presentaciones | 5 de enero de 2026 | 5,90% | Enmienda | — | SEC |
| Caligan Partners LP, David Johnson ×3 presentaciones | 2 de junio de 2023 | — | Presentación inicial | — | SEC |
| Persona informante no revelada | 29 de noviembre de 2001 | — | Presentación inicial | M&A / venta | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 152 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| IDNA · iShares Trust | 3,47% | 131 275 SH | 8 de agosto de 2026 | Diario |
| SAWG · ETF Series Solutions | 2,82% | 1 599 NS | 30 de abril de 2026 | N-PORT |
| CANC · Tema ETF Trust | 2,78% | 96 885 NS | 31 de mayo de 2026 | N-PORT |
| XMHQ · Invesco Exchange-Traded Fund Trust | 2,67% | 2 774 135 SH | 8 de agosto de 2026 | Diario |
| PBE · Invesco Exchange-Traded Fund Trust | 2,59% | 173 519 SH | 8 de agosto de 2026 | Diario |
| MCOW · Pacer Funds Trust | 2,38% | 528 NS | 30 de abril de 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 2,24% | 441 186 NS | 30 de abril de 2026 | N-PORT |
| LYLD · Cambria ETF Trust | 2,01% | 2 722 NS | 30 de abril de 2026 | N-PORT |
| AZTD · Tidal Trust I | 1,92% | 18 950 NS | 30 de abril de 2026 | N-PORT |
| GRPM · Invesco Exchange-Traded Fund Trust | 1,84% | 172 947 SH | 8 de agosto de 2026 | Diario |
| BBP · ETFis Series Trust I | 1,74% | 23 148 NS | 30 de abril de 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 1,61% | 1 596 NS | 30 de abril de 2026 | N-PORT |
| BUL · Pacer Funds Trust | 1,45% | 41 520 NS | 30 de abril de 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1,39% | 306 870 NS | 30 de abril de 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 1,36% | 5 563 NS | 30 de abril de 2026 | N-PORT |
| RFG · Invesco Exchange-Traded Fund Trust | 1,30% | 86 397 SH | 8 de agosto de 2026 | Diario |
| PTH · Invesco Exchange-Traded Fund Trust | 1,29% | 58 887 SH | 8 de agosto de 2026 | Diario |
| COWG · Pacer Funds Trust | 1,26% | 616 432 NS | 30 de abril de 2026 | N-PORT |
| TAX · EA Series Trust | 1,13% | 5 692 NS | 29 de mayo de 2026 | N-PORT |
| CALF · Pacer Funds Trust | 1,07% | 829 382 NS | 30 de abril de 2026 | N-PORT |
| AFMC · First Trust Exchange-Traded Fund VI… | 1,03% | 32 938 NS | 31 de mayo de 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 1,00% | 116 281 NS | 30 de abril de 2026 | N-PORT |
| IBB · iShares Trust | 0,98% | 1 788 613 SH | 8 de agosto de 2026 | Diario |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,93% | 13 681 SH | 8 de agosto de 2026 | Diario |
| AGNG · Global X Funds | 0,92% | 14 988 NS | 31 de mayo de 2026 | N-PORT |
| OASC · Unified Series Trust | 0,91% | 15 171 NS | 31 de mayo de 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,90% | 25 550 NS | 30 de abril de 2026 | N-PORT |
| FLOW · Global X Funds | 0,90% | 5 093 NS | 31 de mayo de 2026 | N-PORT |
| VAMO · Cambria ETF Trust | 0,88% | 16 470 NS | 30 de abril de 2026 | N-PORT |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,72% | 248 016 SH | 8 de agosto de 2026 | Diario |
| FLRG · FIDELITY COVINGTON TRUST | 0,72% | 45 672 NS | 30 de abril de 2026 | N-PORT |
| IJK · iShares Trust | 0,70% | 1 469 020 SH | 8 de agosto de 2026 | Diario |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,69% | 7 149 NS | 31 de mayo de 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,68% | 82 717 NS | 31 de mayo de 2026 | N-PORT |
| BIB · ProShares Trust | 0,66% | 9 600 NS | 31 de mayo de 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,64% | 4 091 NS | 31 de mayo de 2026 | N-PORT |
| VUSE · ETF Series Solutions | 0,63% | 85 930 NS | 31 de mayo de 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,60% | 2 080 NS | 30 de abril de 2026 | N-PORT |
| PDP · Invesco Exchange-Traded Fund Trust | 0,59% | 165 207 SH | 8 de agosto de 2026 | Diario |
| QGRO · AMERICAN CENTURY ETF TRUST | 0,58% | 255 026 NS | 31 de mayo de 2026 | N-PORT |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0,53% | 19 762 NS | 31 de mayo de 2026 | N-PORT |
| VLLU · Harbor ETF Trust | 0,51% | 502 NS | 30 de abril de 2026 | N-PORT |
| VFQY · VANGUARD WELLINGTON FUND | 0,49% | 42 746 SH | 8 de agosto de 2026 | Diario |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,48% | 64 828 NS | 30 de abril de 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,47% | 5 095 NS | 30 de abril de 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,45% | 147 282 SH | 8 de agosto de 2026 | Diario |
| IQSM · New York Life Investments ETF Trust | 0,44% | 30 864 NS | 30 de abril de 2026 | N-PORT |
| XJH · iShares Trust | 0,41% | 33 981 SH | 8 de agosto de 2026 | Diario |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,41% | 47 960 NS | 30 de abril de 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,41% | 33 169 SH | 8 de agosto de 2026 | Diario |